136 related articles for article (PubMed ID: 33559805)
21. Managing advanced prostate cancer with Viadur (leuprolide acetate implant).
Moul JW; Civitelli K
Urol Nurs; 2001 Dec; 21(6):385-8, 393-4; quiz 395-6. PubMed ID: 11998504
[TBL] [Abstract][Full Text] [Related]
22. Characteristics, risk management and GMP standards of pharmaceutical companies in China.
Chen H; Qin L; Jiang C; Qin M; Sun Y; Luo J
Front Public Health; 2023; 11():1103555. PubMed ID: 36969675
[TBL] [Abstract][Full Text] [Related]
23. Record settlement on TAP. Drugmaker pleads guilty to criminal violations.
Taylor M
Mod Healthc; 2001 Oct; 31(41):8. PubMed ID: 11668840
[No Abstract] [Full Text] [Related]
24. Developing a tool for the preparation of GMP audit of pharmaceutical contract manufacturer.
Linna A; Korhonen M; Mannermaa JP; Airaksinen M; Juppo AM
Eur J Pharm Biopharm; 2008 Jun; 69(2):786-92. PubMed ID: 18191391
[TBL] [Abstract][Full Text] [Related]
25. Pharmaceutical Manufacturing in the EU and the EU-US Mutual Recognition Agreement.
Gaspar Ernesto LM; Dias Loureiro RM
PDA J Pharm Sci Technol; 2020; 74(6):617-626. PubMed ID: 32540862
[TBL] [Abstract][Full Text] [Related]
26. Using VigiBase to Identify Substandard Medicines: Detection Capacity and Key Prerequisites.
Juhlin K; Karimi G; Andér M; Camilli S; Dheda M; Har TS; Isahak R; Lee SJ; Vaughan S; Caduff P; Norén GN
Drug Saf; 2015 Apr; 38(4):373-82. PubMed ID: 25687792
[TBL] [Abstract][Full Text] [Related]
27. International Conference on Harmonisation; guidance on good manufacturing practice for active pharmaceutical ingredients; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Sep; 66(186):49028-9. PubMed ID: 12358036
[TBL] [Abstract][Full Text] [Related]
28. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
[TBL] [Abstract][Full Text] [Related]
29. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients.
Tunn UW
BMC Urol; 2011 Jul; 11():15. PubMed ID: 21801354
[TBL] [Abstract][Full Text] [Related]
30. Good Manufacturing Practice for Medicinal Products in Bulgaria: an Analysis of Regulatory Inspection Findings.
Stoimenova AH; Kirilov BJ; Gueorguiev SR; Petkova-Gueorguieva ES; Ognianov SG
Folia Med (Plovdiv); 2020 Mar; 62(1):165-171. PubMed ID: 32337904
[TBL] [Abstract][Full Text] [Related]
31. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
[TBL] [Abstract][Full Text] [Related]
32. Recent Regulatory Trends in Pharmaceutical Manufacturing and their Impact on the Industry.
Tabersky D; Woelfle M; Ruess JA; Brem S; Brombacher S
Chimia (Aarau); 2018 Mar; 72(3):146-150. PubMed ID: 29631666
[TBL] [Abstract][Full Text] [Related]
33. Leuprolide implant approved for once-yearly palliative treatment of advanced prostate cancer.
Oncology (Williston Park); 2000 Jun; 14(6):828, 830. PubMed ID: 10887633
[No Abstract] [Full Text] [Related]
34. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
D'Hooghe T
Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
36. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
World Health Organ Tech Rep Ser; 2003; 917():i-viii, 1-125, back cover. PubMed ID: 15024913
[TBL] [Abstract][Full Text] [Related]
37. Correcting India's Chronic Shortage of Drug Inspectors to Ensure the Production and Distribution of Safe, High-Quality Medicines.
Kadam AB; Maigetter K; Jeffery R; Mistry NF; Weiss MG; Pollock AM
Int J Health Policy Manag; 2016 Sep; 5(9):535-542. PubMed ID: 27694680
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.
Kobayashi M; Nukui A; Suzuki K; Kurokawa S; Morita T
Int J Clin Oncol; 2011 Dec; 16(6):630-6. PubMed ID: 21512893
[TBL] [Abstract][Full Text] [Related]
40. Implantable LHRH agonist for treatment of prostate cancer.
Lajiness MJ
Urol Nurs; 2006 Oct; 26(5):408, 414. PubMed ID: 17078331
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
